



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Bot et al.

Filing Date
March 8, 2001

Group
163



U.S. PATENT DOCUMENTS

| *Exam. Init. | Document No. | | | | | | | | Date | Name | Class | Subclass | Filing Date if Appropriate |
|-----------------|--------------|---|---|---|---|---|---|--|-----------|---------------|-------|----------|-------------------------------|
| 9w | 6 | 2 | 0 | 4 | 2 | 5 | 0 | | 3/20/2001 | Bot et al. | | | |
| 1 | 5 | 9 | 6 | 9 | 1 | 0 | 9 | | 10/19/99 | Bona et al. | | | |
| | 5 | 5 | 8 | 0 | 8 | 5 | 9 | | 12/3/96 | Fegner et al. | | | |
| | 5 | 5 | 8 | 9 | 4 | 6 | 6 | | 12/31/96 | Fegner et al. | | | |

FOREIGN PATENT DOCUMENT

| | Document No. | | | | | | | | Date | Country | Class | SubClass | Translation Yes No | |
|----|--------------|---|---|---|---|---|---|--|---------|---------|-------|----------|-----------------------|--|
| 9w | 9 | 4 | 2 | 1 | 7 | 9 | 7 | | 9/29/94 | WIPO | | | | |
| 9w | 9 | 0 | 1 | 1 | 0 | 9 | 2 | | 10/4/90 | WIPO | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

| | | | | | | | | | | | | | |
|----|--|--|---|--|--|--|--|--|--|--|--|--|--|
| 9w | | | Bot et al., 1999, "Induction of antibody response by DNA immunization of newborn baboons against influenza virus." <i>Viral Immunol</i> 12:91-6. | | | | | | | | | | |
| 1 | | | Bot et al., 1997, "Induction of humoral and cellular immunity against influenza by immunization of newborn mice with a plasmid bearing a hemagglutinin gene", <i>International Immunology</i> , Vol. 9, No. 11, pp.101-111. | | | | | | | | | | |
| 1 | | | Bot et al., 1997, "Immune Response of Neonates Elicited by Somatic Transgene Vaccination with Naked DNA", <i>Frontiers in Bioscience</i> 2, d173-188. | | | | | | | | | | |

NY02:424845.1

1

Examiner

Joe W. W. W.

Date Considered

9/29/03

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Bot et al.

Filing Date
March 8, 2001

Group
1632



Verma *et al.*, Sept. 1997, "Gene Therapy-Promises, Problems, and Prospects," *Nature*, vol. 389: 239-242.

Bot *et al.*, 1996, "Cellular Mechanisms Involved in Protection and Recovery from Influenza Virus Infection in Immunodeficient Mice", *J. Virol.* 70: 5668-5672.

Bot *et al.*, 1996, "DNA immunization of newborn mice with a plasmid-expressing nucleoprotein of influenza virus," *Viral Immunology* 9:207-210.

Forsthuber *et al.* 1996, "Induction of TH1 and TH2 immunity in neonatal mice," *Science* 271:1728-1730.

Bot *et al.*, 1996, "Kinetics of generation and persistence on membrane class II molecules of a vira peptide expressed on foreign and self proteins." *J Immunol.* 157:3436-42.

Mor *et al.* 1996, "Induction of neonatal tolerance by plasmid DNA vaccination of mice," *J. Clin. Invest.* 98:2700-2705.

Ridge *et al.* 1996, "Neonatal tolerance revisited: turning on newborn T cells with dendritic cells," *Science* 271:1723-1726.

Sarzotti *et al.* 1996, "Induction of protective CTL responses in newborn mice by a murine retrovirus," *Science* 271:1726-8.

Crowe, J.E. 1995, "Respiratory syncytial virus vaccine development," *Vaccine* 4:415-421.

Davis *et al.*, 1995, "DNA-based immunization", *Molecular and Cell Biology of Human Disease Series*, 5: 368-387.

Donnelly *et al.*, 1995, "Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus," *Nature Med.* 1:583-587.

NY02:424845.1

2

Examiner

Jae W. Oltach

Date Considered

9/29/03

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Bot et al.

Filing Date
March 8, 2001

Group
1632



Justewicz *et al.*, 1995, "Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin," *J. Virol.* 69:7712-7717.

Martins *et al.*, 1995, "DNA Vaccination against Persistent Viral Infection", *J. Virol.* 69: 2574-2582.

Marshall, E. August 1995, "Gene Therapy's Growing Pains," *Science*, 269: 1050-1055.

Orkin *et al.* Dec. 1995 "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," NIH Report and Recommendation.

Stedman's Medical Dictionary, 1995, 26th Edition., "pathogen" p.1312, Spraycar, M., Ed., Williams & Wilkins, publ.

Bachmann *et al.*, "In vivo versus in vitro assays for assessment of T- and B- cell function" *Current Opinion in Immunology*, 6:320-326, 1994.*

Donnelly, *et al.* 1994, "Immunization with DNA," *Journal of Immunological Methods*, 176:145-152.

Isobe *et al.*, 1994, "Intact antiinfluenza virus immune response in targeted kappa-deficient mice," *Viral Immunol.* 7:25-301.

Katsumi *et al.* 1994, "Humoral and cellular immunity to an encoded protein induced by direct DNA injection," *Human Gene Therapy* 5:1335-1339.

Ozaki *et al.* 1994, "Investigation of varicella-zoster virus DNA by the polymerase chain reaction in healthy children with varicella vaccination," *Journal of Medical Virology* 42:47-51.

Rossiter *et al.*, 1994, "Processing of viable group A streptococci leads to major histocompatibility complex class II presentation of T cell epitopes from the major protective antigen," *Eur. J. Immunol.* 24:1244-1247.

Vordermeier *et al.*, 1994, "Promiscuous T cell recognition of an H-2 IA-presented mycobacterial epitope," *Eur. J. Immunol.* 24:2061-2067.

NY02:424845.1

3

Examiner

Joe Watach

Date Considered

1/21/03

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Bot et al.

Filing Date
March 8, 2001

Group
1632



Assateerawatt *et al.* 1993, "Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults," *Asia Pacific Journal of Allergy and Immunology*. vol. 11: 85-91.

Lai *et al.* 1993, "Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs plasma-derived vaccine in children: immunogenicity and anamnestic responses," *Hepatology*, vol. 18: 763-767.

del Canho *et al.* 1993, "Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccines in healthy neonates: a comparison of three different vaccination schemes," vol. 41: 30-34

Doherty, R. 1993, "Hepatitis viruses and protection against infection in children," *Current Opinion in Pediatrics*. 5:3-13.

Fynan *et al.*, 1993, "DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations," *Proc. Natl. Acad. Sci. U.S.A.* 90:11478-11482.

Mulligan, R.C. 1993, "The Basic Science of Gene Therapy," *Science*, vol. 260: 926-932.

Montgomery *et al.*, 1993, "Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors," *DNA and Cell Biology* 12:777-783.

Ulmer *et al.*, 1993, "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein", *Science* 259:1745-1748.

Kuzu *et al.*, 1993, "In vivo priming effect during various stages of ontogeny of an influenza A virus nucleoprotein peptide", *Eur. J. Immunol.* 23:1397-1400.

De Magistris, 1992, "Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor," *Cell* 68:625-634.

Li *et al.*, 1992, "Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes," *J. Virol.* 66:399-404.

Nelson *et al.*, 1992, "Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-Ak," *Proc. Natl. Acad. Sci. U.S.A.* 89:7380-7383.

NY02:424845.1

4

Examiner

Joe W. Wanta

Date Considered

9/29/03

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Bot et al.

Filing Date
March 8, 2001

Group
1632



Partidos *et al.*, 1992, "The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides," *Eur. J. Immunol.* 22:2675-2680.

Zaghoulani *et al.*, 1992, "Cells expressing an H chain Ig gene carrying a viral T cell epitope are lysed by specific cytolytic T cells," *J. Immunol.* 148:3604-3609.

Leclerc *et al.*, 1991, "The cellular location of a foreign B cell epitope expressed by recombinant bacteria determines its T cell-independent or T cell-dependent characteristics," *J. Immunol.* 147:3545-3552.

Ho *et al.*, 1990, "Identification of two promiscuous T cell epitopes from tetanus toxin," *Eur. J. Immunol.* 20:477-483.

Taylor *et al.*, 1987, "Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells," *Immunogenetics* 26:267-272.

Benjamini and Leskowitz, 1988, "Immunology, A Short Course", Alan R. Liss, Inc., New York, p 65.

Clarke *et al.* 1987, "Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein," *Nature* 330:381-384.

Lai *et al.*, 1986, "Use of the hepatitis B recombinant DNA yeast vaccine (H-B-Vax II) in children: two doses vs three doses of 5 micrograms regime; an interim report," *J. of Infection*, vol. 13, Suppl. A: 19-25.

Taylor and Askonas 1986, "Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo," *Immunology*, 58:417-420.

Caton *et al.* 1982, "The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)," *Cell* 31:417-427.

Rubinstein *et al.* 1982, "Idiotypic-anti-idiotypic network. II. Activation of silent clones by treatment at birth with idiotypes is associated with the expansion of idiotype-specific helper T cells," *J. Exp. Med.* 156:506-521.

Townsend and Skehel. 1982, "Influenza A specific cytotoxic T-cell clones that do not recognize viral glycoproteins," *Nature* 300:655-657.

NY02:424845.1

5

Examiner

Joe Winters

Date Considered

9/29/03


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Bot et al.

Filing Date
March 8, 2001

Group
1632



Kilbourne, 1976, "Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans," *J. Infect. Dis.* 134:384-394

Zinhernagel and Doherty. 1974, "Restriction of *in vitro* Tcell-mediated cytotoxicity in lymphocytic choriomeningitis within in a syngeneic or semiallogeneic system," *Nature* 248:701-702.

Billingham, 1956, "Quantitative studies on tissue transplantation immunity - III. Actively acquired tolerance," *Proc. R. Soc. London Ser. B.* 239:44:359-412.

Billingham *et al.*, 1953, "Actively acquired tolerance of foreign cells," *Nature* 172:603-606.

Owen, 1945, "Immunogenetic consequences of vascular anastomoses between bovine twins," *Science* 102:400-401.

NY02:424845.1

6

Examiner

John W. Bartal

Date Considered

9/29/03

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.